热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 药物靶点和Fc受体 药物靶点

所有图片（1/2）

Bcl-x/BCL2L1 Protein, Human

Bcl2-L-1,Apoptosis regulator Bcl-X,BCL2L,BCLX

价格 ￥950.00 （ 供应商现货 ： 3-5个工作日）
货号 UA011327
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 物种

    Human

  • 分子别名

    Bcl2-L-1, Apoptosis regulator Bcl-X, BCL2L, BCLX

  • Accession

    Q07817

  • 表达序列

    Ser2- Arg212

  • 表达宿主

    E.coli

  • 分子量

    20-30kDa (Reducing)

  • 纯度

    ＞90% by SDS-PAGE

  • 活性

    Immobilized BID His Tag Protein, Human (Cat. No. UA016067) at 10.0μg/mL (100μL/well) can bind Biotinylated Bcl-x/BCL2L1 Protein, Human (Cat. No. UA011327) with EC50 of 4.56-7.53 ng/mL.

  • 标记

    Unconjugated

  • 标签

    No Tag

  • 性状

    Lyophilized Powder

  • 缓冲体系

    PBS, PH7.4, 5% trehalose

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    1.Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993 Aug 27;74(4):597-608.
    2.Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 1996 May 23;381(6580):335-41.
    3.Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008 May 1;68(9):3421-8.

背景介绍

  • Bcl-x (BCL2L1) is an important anti-apoptotic protein in the Bcl-2 family, featuring two major isoforms: Bcl-xL (long form, anti-apoptotic) and Bcl-xS (short form, pro-apoptotic). Bcl-xL contains BH1-4 domains and a C-terminal transmembrane region, and inhibits mitochondrial outer membrane permeabilization by sequestering Bax/Bak or BH3-only proteins (such as Bim and Bad). Beyond regulating apoptosis, Bcl-xL suppresses autophagy through binding to Beclin-1 and participates in mitochondrial homeostasis maintenance. Bcl-xL is highly expressed in various solid tumors and is associated with chemotherapy resistance and poor prognosis; although BH3 mimetics targeting Bcl-xL (such as Navitoclax) demonstrate anti-tumor activity, their clinical application is limited by dose-limiting thrombocytopenia, as Bcl-xL is essential for platelet survival. Current research is shifting toward selective Bcl-xL inhibitors or PROTAC degradation strategies to overcome this toxicity.

  • 电泳

    • 1μg (R: reducing condition, N:non-reducing condition).

  • ELISA

    • Immobilized BID His Tag Protein, Human (Cat. No. UA016067) at 10.0μg/mL (100μL/well) can bind Biotinylated Bcl-x/BCL2L1 Protein, Human (Cat. No. UA011327) with EC50 of 4.56-7.53 ng/mL.

评论(0)